Zimmer Biomet Holdings, Inc.(NYSE:ZBH) Receives $165.65 Average PT from Analysts Posted by Lars Charter on Mar 28th, 2021 Tweet
Shares of Zimmer Biomet Holdings, Inc.(NYSE:ZBH) have earned a consensus rating of “Buy” from the twenty-five analysts that are currently covering the firm, MarketBeat Ratings reports.Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, fifteen have assigned a buy recommendation and three have issued a strong buy recommendation on the company.The average 12-month target price among brokerages that have covered the stock in the last year is $165.65.
ZBH has been the topic of several research reports.
Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating and set a $167.00 price target on the stock.in a research note on Wednesday, February 10th.Needham & Company LLC upped their price target on Zimmer Biomet from $185.00 to $192.00 and gave the company a “strong-buy” rating in a research note on Friday, February 5th.
Raymond James upped their price objective on Zimmer Biomet from $170.00 to $187.00 and gave the company a “strong-buy” rating in a report on Monday, February 8th.Wells Fargo & Company upped their price objective on Zimmer Biomet from $176.00 to $183.00 and gave the company an “overweight” rating in a report on Monday, March 8th.Finally, Truist Financial upped their price objective on Zimmer Biomet from $152.00 to $174.00 in a report on Wednesday, January 6th.Get Zimmer Biomet alerts:
Several large investors have recently bought and sold shares of ZBH.
BlackRock Inc.grew its holdings in shares of Zimmer Biomet by 23.9% during the fourth quarter.
BlackRock Inc.now owns 19,395,694 shares of the medical equipment provider’s stock worth $2,988,683,000 after buying an additional 3,738,953 shares in the last quarter.Viking Global Investors LP grew its holdings in shares of Zimmer Biomet by 128.8% during the fourth quarter.Viking Global Investors LP now owns 3,867,074 shares of the medical equipment provider’s stock worth $595,877,000 after buying an additional 2,176,989 shares in the last quarter.
Norges Bank bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $304,733,000.JPMorgan Chase & Co.grew its holdings in shares of Zimmer Biomet by 5.3% during the third quarter.JPMorgan Chase & Co.now owns 9,756,997 shares of the medical equipment provider’s stock worth $1,301,582,000 after buying an additional 490,415 shares in the last quarter.Finally, Polar Capital LLP bought a new position in shares of Zimmer Biomet during the third quarter worth about $58,560,000.
Institutional investors and hedge funds own 87.17% of the company’s stock.ZBH stock traded up $3.67 during trading on Thursday, hitting $161.32.The company had a trading volume of 655,775 shares, compared to its average volume of 1,311,153.The company has a fifty day moving average price of $160.11 and a two-hundred day moving average price of $150.42.The company has a current ratio of 2.18, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.The company has a market cap of $33.61 billion, a P/E ratio of 1,008.31, a P/E/G ratio of 4.32 and a beta of 1.34.
Zimmer Biomet has a fifty-two week low of $88.00 and a fifty-two week high of $170.05.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 4th.The medical equipment provider reported $2.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.05.The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.08 billion.Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%.Zimmer Biomet’s quarterly revenue was down 1.9% on a year-over-year basis.During the same quarter in the previous year, the firm earned $2.30 EPS.
On average, analysts expect that Zimmer Biomet will post 4.8 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 30th.Investors of record on Monday, March 29th will be issued a dividend of $0.24 per share.The ex-dividend date is Friday, March 26th.This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.60%.Zimmer Biomet’s payout ratio is presently 12.20%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services.It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
See Also: Cryptocurrencies Receive News & Ratings for Zimmer Biomet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter ..
